Abstract
Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10. In the last decade, HSP60 has been detected in the cytosol, the cell surface, the extracellular space, and biological fluids. HSP60 elicits potent proinflammatory response in cells of the innate immune system and serves as a danger signal of stressed or damaged cells. As cytosolic HSP60 levels gradually increase or decrease during carcinogenesis in various organs, HSP60 can be used as a biomarker for the diagnosis and prognosis of preneoplastic and neoplastic lesions. In this review, we summarize recent discoveries on the important roles of HSP60 in various diseases ranging from autoimmune diseases to tumors. Furthermore, small molecules targeting HSP60, which were the target of intensive investigations in the last few years, are also summarized. The possibility of utilizing HSP60 as a new drug target for the treatment of certain diseases is examined.
Keywords: HSP60, molecular chaperone, apoptosis, proinflammatory response, biomarker, carcinogenesis, inhibitor, cell stress, diagnosis, prognosis.
Current Pharmaceutical Design
Title:HSP60 as a Drug Target
Volume: 19 Issue: 3
Author(s): Hiroyuki Nakamura and Hidemitsu Minegishi
Affiliation:
Keywords: HSP60, molecular chaperone, apoptosis, proinflammatory response, biomarker, carcinogenesis, inhibitor, cell stress, diagnosis, prognosis.
Abstract: Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10. In the last decade, HSP60 has been detected in the cytosol, the cell surface, the extracellular space, and biological fluids. HSP60 elicits potent proinflammatory response in cells of the innate immune system and serves as a danger signal of stressed or damaged cells. As cytosolic HSP60 levels gradually increase or decrease during carcinogenesis in various organs, HSP60 can be used as a biomarker for the diagnosis and prognosis of preneoplastic and neoplastic lesions. In this review, we summarize recent discoveries on the important roles of HSP60 in various diseases ranging from autoimmune diseases to tumors. Furthermore, small molecules targeting HSP60, which were the target of intensive investigations in the last few years, are also summarized. The possibility of utilizing HSP60 as a new drug target for the treatment of certain diseases is examined.
Export Options
About this article
Cite this article as:
Nakamura Hiroyuki and Minegishi Hidemitsu, HSP60 as a Drug Target, Current Pharmaceutical Design 2013; 19 (3) . https://dx.doi.org/10.2174/1381612811306030441
DOI https://dx.doi.org/10.2174/1381612811306030441 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry The Role of Neutrophil Proteases in LPS-Induced Production of Regulatory Rheumatoid Factor that Suppresses Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Case-control Association Study of Autoimmunity Associated Variants in PDCD1 and Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pattern Recognition Receptors and Control of Innate Immunity: Role of Nucleic Acids
Current Pharmaceutical Biotechnology Therapeutic Blockade of TCR Signal Transduction and Co-Stimulation in Autoimmune Disease
Current Drug Targets - Inflammation & Allergy Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery Targeting Cytokines of the Interleukin-12 Family in Autoimmunity
Current Medicinal Chemistry Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued)